Fig. 1: Overall vaccine effectiveness against COVID-19-related ICU admissions and death of mRNA-based second vaccine boosters for each week, March 7 through August 15, 2022. | Nature Communications

Fig. 1: Overall vaccine effectiveness against COVID-19-related ICU admissions and death of mRNA-based second vaccine boosters for each week, March 7 through August 15, 2022.

From: Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile

Fig. 1

3mRNA denotes individuals who received a BNT162b2 primary series plus a homologous first booster dose. CC+mRNA, CCC, and CCA denote individuals with a primary series of CoronaVac plus a first mRNA, homologous, and a ChAdOx-1 first booster dose, respectively. Vaccine effectiveness estimates are presented as point estimates with standard 95% Wald confidence intervals. The corresponding numerical values for vaccine effectiveness against COVID-19-related ICU admissions and deaths are shown in Supplementary Tables S6 and S7, respectively.

Back to article page